Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis

  • Authors:
    • Atsushi Sekiya
    • Shiro Suzuki
    • Ayako Tanaka
    • Satomi Hattori
    • Yusuke Shimizu
    • Nobuhisa Yoshikawa
    • Yoshihiro Koya
    • Hiroaki Kajiyama
    • Fumitaka Kikkawa
  • View Affiliations

  • Published online on: July 17, 2019     https://doi.org/10.3892/ijo.2019.4845
  • Pages: 755-765
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Refractory peritoneal carcinomatosis is a common terminal feature of epithelial ovarian cancer (EOC). Previous reports have suggested that immunotherapy is a promising therapeutic strategy for EOC. Interleukin (IL)‑33 is a member of the IL‑1 superfamily of cytokines. The role of IL‑33 in tissue inflammation and promoting type 2 immune responses has been established, and recently, there is accumulating evidence to suggest the involvement of IL‑33 in carcinogenesis. In this study, we focused on the association between the tumor expression of IL‑33 and ovarian peritoneal carcinomatosis. We used an immunosufficient murine model of peritoneal carcinomatosis and human EOC samples. The overexpression of IL‑33 in the ID8 mouse EOC cell line tumors significantly prolonged the survival of immunocompetent mice in the peritoneal carcinomatosis setting, but not in the subcutaneous model. In addition, the silencing of IL‑33 in ID8‑T6 cells (subclone with high dissemination potential) significantly shortened the survival of the tumor‑bearing mice. This was likely due to the intratumoral accumulation of CD8+ and CD4+ T cells, and a decrease in CD11b+Gr1+ cells. Furthermore, IL‑33 induced the intraperitoneal microenvironment favoring tumor elimination through the inhibition of differentiation into CD11b+Gr1+ cells. On the whole, the findings of this study suggest IL‑33 to be a cytokine that reflects antitumor peritoneal conditions. Further investigation of the antitumorigenic role of IL‑33 may aid in the development of more effective therapeutic approaches for the treatment of EOC with peritoneal carcinomatosis.
View Figures
View References

Related Articles

Journal Cover

September 2019
Volume 55 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sekiya, A., Suzuki, S., Tanaka, A., Hattori, S., Shimizu, Y., Yoshikawa, N. ... Kikkawa, F. (2019). Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis. International Journal of Oncology, 55, 755-765. https://doi.org/10.3892/ijo.2019.4845
MLA
Sekiya, A., Suzuki, S., Tanaka, A., Hattori, S., Shimizu, Y., Yoshikawa, N., Koya, Y., Kajiyama, H., Kikkawa, F."Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis". International Journal of Oncology 55.3 (2019): 755-765.
Chicago
Sekiya, A., Suzuki, S., Tanaka, A., Hattori, S., Shimizu, Y., Yoshikawa, N., Koya, Y., Kajiyama, H., Kikkawa, F."Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis". International Journal of Oncology 55, no. 3 (2019): 755-765. https://doi.org/10.3892/ijo.2019.4845